Carsten Brunn, PH.D.

President and Ceo

Prior to leading Selecta, Dr. Brunn was the President of Pharmaceuticals for the Americas Region at Bayer and a member of the Global Pharmaceutical Executive Committee. Prior to being appointed to that role in 2017, he was the President of Bayer Pharmaceuticals in Japan, a role he had held since 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Over the last 25 years, Dr. Brunn has held a number of senior leadership positions in Europe, Asia, and the United States at leading companies such as Eli Lilly, Novartis, Basilea, and Bausch & Lomb. Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Sciences. In addition, he studied at the University of Washington under a research scholarship. He received his Ph.D. in Chemistry from the University of Hamburg, Germany, and completed his executive education at London Business School.

Lloyd Johnston, PH.D.

Chief Operations Officer

Prior to joining Selecta Biosciences in 2008, Dr. Johnston spent 9 years at Alkermes, ascending to the role of Vice President of Operations with responsibility for process development, scale‑up, and clinical manufacturing of pulmonary and sustained-release injectable products, as well as leadership of Alkermes’ manufacturing facility in Chelsea, Massachusetts. He was also a project leader and a member of steering committees at Alkermes for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research, or AIR, a private company formed in 1998 and acquired by Alkermes in 1999. Prior to joining AIR, he was a lecturer in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.Sc. in Chemical Engineering from Queen’s University in Ontario, Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

Takashi Kei Kishimoto, PH.D.

Chief Science Officer

Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, where he served in several leadership positions over the course of 5 years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology and cardiovascular disease. Prior to working at Momenta, he served as Senior Director of Inflammation Research at Millennium Pharmaceuticals from 1999 to 2006, where he provided the scientific leadership for 4 programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell and The New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University.

kristen baldwin

chief people officer

Kristen Baldwin brings 20+ years of Human Resource and Consulting experience to Selecta Biosciences. Most recently, Kristen served in a dual capacity as the Chief People Officer for the LIVEKINDLY Collective, a high growth plant-based foods company, and as a Senior Partner at CEO.works, a cutting-edge Human Capital consulting firm. Kristen served the prior decade in senior HR roles at Bayer and Otsuka Pharmaceuticals, where she was instrumental in leading transformation and culture initiatives aimed to drive value creation for the enterprise.

Her certifications include: Talent to Value Coach, Senior Professional in HR, Project Management Professional, and Prosci Change Practitioner (business process reengineering & change management).

Kristen holds an MBA from Columbia University and a Bachelor of Science in Organizational Communication from Ohio University.

Peter G. traber, M.D.

Chief Medical Officer

Prior to joining Selecta Biosciences in 2020, Dr. Traber spent 2 years as a Partner at Alacrita Consulting, providing drug development consulting services and served as the interim Chief Medical Officer (CMO) for Morphic Therapeutic supporting integrin inhibitor drug development. For the 8 years prior, he was CEO, CMO, and on the Board of Galectin Therapeutics developing drugs for fibrotic liver disease and cancer. He served as CMO and SVP of Clinical Development and Medical Affairs at GSK, CEO of Baylor College of Medicine, and Chair of Medicine and CEO of the University of Pennsylvania Health System. Dr Traber managed an academic research laboratory and has published more than 100 research articles, reviews, and book chapters. He received his MD from Wayne State School of Medicine, a BS in Chemical Engineering from the University of Michigan, and a certificate in Medical Leadership from Wharton Business School. He is currently an Adjunct Professor of Medicine at the University of Pennsylvania and serves on the board of Caladrius Biosciences.

Kevin Tan

Chief Financial Officer

Prior to joining Selecta Biosciences in 2021 Kevin was the Treasurer at Sarepta Therapeutics, responsible for the liquidity and capital management of the company.  He led numerous financings across equity and debt markets and was a key member of the Business Development team.

Before Sarepta, Kevin had an extensive career in financial services.  Most recently, as Senior Portfolio Manager at a Canadian pension fund, Kevin managed billions in capital across the public markets. 

Kevin holds a Bachelor of Commerce (Honors) from Queen’s University at Kingston, a Master of Engineering (Operations Research & Financial Engineering) from Princeton University and an MBA from The University of Chicago Booth School of Business. 

carrie S. Cox

Chairman

Ms. Cox most recently served as Executive Chair of Humacyte, Inc., where she also held the title of CEO from 2010 to 2018. From 2003 until 2009, she held the positions of Executive Vice President and President, Global Pharmaceuticals, at Schering-Plough. During her tenure, Ms. Cox oversaw the company’s global prescription pharmaceutical business, which generated approximately $16 billion in annual sales, with a 5-year CAGR of 22%. Previous roles include President, Global Prescription Business at Pharmacia Corporation, and Senior Vice President of Global Business Management at Pharmacia & Upjohn. She currently serves on the Boards of Directors of Texas Instruments and Cardinal Health, and holds the position of Chair of electroCore. Ms. Cox has also served on the Board of Celgene, as Lead Director for Texas Instruments, as Chairman of Array BioPharma, and as Chairman of Prism Pharmaceutical. She has been named to FORTUNE magazine’s list of the “50 Most Powerful Women in Business” six times. Her work has been featured in the Harvard Business Review, and in the New York Times bestseller, The Profit Zone. She received her B.S. from Massachusetts College of Pharmacy in 1981, and was a registered pharmacist.

goran A. Ando, M.D.

Director

Dr. Ando brings 37 years of experience as one of the most experienced and respected leaders in the global pharmaceutical industry. Dr. Ando is the retired Chairman of the Board of Novo Nordisk A/S, a global pharmaceutical company with $120 billion market capitalization.

Dr. Ando began his career in the pharmaceutical industry in 1978 as Medical Director of Pfizer AB, progressing to Director, Clinical Research with Pfizer International in the U.S. Dr. Ando then became VP, Medical and Scientific Affairs at Bristol-Myers and returned to Sweden as President of the Astra Research Centre. Between 1989 and 1995, he held various senior appointments at Glaxo, including Research & Development Director for Glaxo Group Research.

Dr. Ando joined Pharmacia AB in 1995 as Executive Vice President and Deputy CEO, moving to the U.S. in 1997 to lead R&D with additional responsibilities for manufacturing, information technology, business development, and M&A. During his eight-year tenure as Head of R&D at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food & Drug Administration prior to Pharmacia’s acquisition by Pfizer for $60 billion.

Dr. Ando was then appointed CEO of Celltech Group PLC in the United Kingdom, one of the most successful European biotech companies, until it was acquired by UCB Pharma for $3 billion in 2005.

Dr. Ando is the retired Chairman of Novo Nordisk A/S, and is currently Chairman of EyePoint Pharmaceuticals, and a board member of Parexel, Tessa Therapeutics and EUSA Pharma.

Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.

Timothy Barabe

Director

Timothy C. Barabe joined our board of directors in July 2016. Mr. Barabe also serves on the boards of ArQule, Inc., Veeva Systems Inc., and Vigilant Biosciences, Inc., a private company. Mr. Barabe retired in June 2013 from his position as Executive Vice President and Chief Financial Officer of Affymetrix, Inc. Prior to this, Mr. Barabe has served in senior executive positions in finance and management for companies including Human Genome Sciences, Inc, Regent Medical Limited, a U.K.-based, privately owned, surgical supply company, and Sandoz GmbH, the generic pharmaceutical subsidiary of Novartis. Mr. Barabe received his MBA degree from the University of Chicago.

Nishan de silva, M.D.

Director

Dr. de Silva brings over 20 years of experience in biotechnology operations, biopharmaceutical venture capital, and healthcare management consulting. He is currently chief executive officer and director of AFYX Therapeutics, a private venture-backed biotechnology company focusing on addressing unmet needs in mucosal diseases.  He previously served as president, chief operating officer, and director of Poseida Therapeutics (PSTX), a cell and gene therapy-focused biopharmaceutical company, where he oversaw clinical development, regulatory, manufacturing, finance, and business development activities. Prior to Poseida, he was chief financial officer and vice president of finance and strategy at Ligand Pharmaceuticals Inc. (LGND). Earlier in his career, Dr. de Silva served as a principal at private equity firm Warburg Pincus LLC, responsible for late-stage biopharmaceutical investment opportunities, and was an engagement manager at McKinsey & Company. He holds a B.A. summa cum laude in biology from Harvard University, an M.D. from The University of Pennsylvania School of Medicine and an M.B.A. with Distinction in healthcare management from The Wharton School.

Scott D. Myers, MBA

Director

Scott Myers joined the Selecta Biosciences board in June of 2019. Previously, Scott Myers served as President and Chief Executive Officer of AMAG Pharmaceuticals, Inc. a public biopharmaceutical company focused on bringing innovative products to patients with unmet medical needs. Prior to AMAG Pharmaceuticals, Mr. Myers served as Chairman and Chief Executive Officer of Rainier Therapeutics, a private, clinical-stage biotechnology company focused on metastatic bladder cancer. Prior to joining Rainier, Mr. Myers was Chief Executive Officer, President and Director of Cascadian Therapeutics until it was acquired by Seattle Genetics in March 2018. He was also CEO of Aerocrine AB (a Swedish Medtech company) from September 2011 until its acquisition by Circassia, PLC in July of 2015. He has held senior commercial operations, general management and information management positions for UCB SA, a Belgium-based biopharmaceutical company, and Johnson & Johnson.

Mr. Myers serves as a member of the Nominating and Corporate Governance Committee as well as Chairman of the Compensation Committee here at Selecta.

Scott is also an Independent Director for the following companies: Trillium Therapeutics (Nasdaq: TRIL), Harpoon Therapeutics (Nasdaq: HARP) and Dynavax Technologies (Nasdaq: DVAX) where he is also Chairman of the Board.  Myers earned his B.A. in biology from Northwestern University and his M.B.A. from the University of Chicago’s Graduate School of Business (Booth).

aymeric Sallin, M.S.

Director
Founder & CEO, Nanodimension

Aymeric Sallin, M.S., has served as a member of our board of directors since 2008. Mr. Sallin has served as the Chief Executive Officer of NanoDimension, a venture capital firm, since 2002 and is the founder of that firm. He currently serves as a board member of H55, CROCUS Technology, and Tarveda Therapeutics. Mr. Sallin is also a member of the Swiss Academy of Engineering Science and has served as a strategic advisory board member of the École Polytechnique Fédérale de Lausanne, or EPFL. Mr. Sallin has worked to promote nanotechnology around the world, and has received the NSTI Fellow Award and 2012 EPFL Alumni Award for his contribution to the field of nanotechnology. Mr. Sallin received his M.A. in Physical Engineering from EPFL in Lausanne, Switzerland.

Timothy springer, PH.D.

Director
Professor, Harvard Medical School and Children’s Hospital Boston

Timothy A. Springer, Ph.D., has served as a member of our board of directors since June 2016 and as a scientific advisor to us since December 2008. Dr. Springer has most recently served as the Latham Family Professor at Harvard Medical School. Dr. Springer was the founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. Dr. Springer is a member of the National Academy of Sciences and his honors include the Crafoord Prize, the American Association of Immunologists Meritorious Career Award, the Stratton Medal from the American Society of Hematology, and the Basic Research Prize from the American Heart Association. Dr. Springer received his Ph.D. from Harvard University.

Patrick zenner

Director

Patrick Zenner served as President and Chief Executive Officer of Hoffmann-La Roche Inc., North America—the prescription drug unit of the Roche Group. Prior to his retirement, Mr. Zenner spent 32 years at Roche. Mr. Zenner currently serves as Chairman of the Board and a director of both ArQule, Inc., and West Pharmaceutical Services, Inc. Mr. Zenner received his M.B.A. from Fairleigh Dickinson University.

Carsten brunn, PH.D.

President and CEO

Prior to leading Selecta, Dr. Brunn was the President of Pharmaceuticals for the Americas Region at Bayer and a member of the Global Pharmaceutical Executive Committee. Prior to being appointed to that role in 2017, he was the President of Bayer Pharmaceuticals in Japan, a role he had held since 2013. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing innovative pharmaceutical companies in Japan. Over the last 25 years, Dr. Brunn has held a number of senior leadership positions in Europe, Asia, and the United States at leading companies such as Eli Lilly, Novartis, Basilea, and Bausch & Lomb. Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Sciences. In addition, he studied at the University of Washington under a research scholarship. He received his Ph.D. in Chemistry from the University of Hamburg, Germany, and completed his executive education at London Business School.